• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Alector Inc (NQ: ALEC )

    5.020 +0.100 (+2.03%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Alector Inc

    < Previous 1 2 Next >
    Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
    From Alector, Inc.
    Via GlobeNewswire
    Alector to Participate in Upcoming Healthcare Conferences
    From Alector, Inc.
    Via GlobeNewswire
    Alector Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Alector, Inc.
    Via GlobeNewswire
    Alector to Host Mid-Year Earnings Conference Call
    Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT 
    From Alector, Inc.
    Via GlobeNewswire
    Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
    From Alector, Inc.
    Via GlobeNewswire
    Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024
    From Alector, Inc.
    Via GlobeNewswire
    Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
    From Alector, Inc.
    Via GlobeNewswire
    Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform
    Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation 
    From Alector, Inc.
    Via GlobeNewswire
    Alector to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
    From Alector, Inc.
    Via GlobeNewswire
    Alector to Participate in Upcoming Healthcare Conferences
    From Alector, Inc.
    Via GlobeNewswire
    Alector Reports First Quarter 2024 Financial Results and Provides Business Update
    From Alector, Inc.
    Via GlobeNewswire
    Alector to Participate in Upcoming Healthcare Conferences
    From Alector, Inc.
    Via GlobeNewswire
    Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
    From Alector, Inc.
    Via GlobeNewswire
    Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call
    Call Scheduled for Tuesday, February 27, 2024, at 4:30 p.m. ET/1:30 p.m. PT 
    From Alector, Inc.
    Via GlobeNewswire
    Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
    The trial, being conducted in partnership with GSK, is expected to enroll approximately 282 patients globally 
    From Alector, Inc.
    Via GlobeNewswire
    FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
    From Alector, Inc.
    Via GlobeNewswire
    Alector Announces Closing of Public Offering
    From Alector, Inc.
    Via GlobeNewswire
    Alector Announces Pricing of Public Offering of Common Stock
    From Alector, Inc.
    Via GlobeNewswire
    Alector Announces Proposed Public Offering of Common Stock
    From Alector, Inc.
    Via GlobeNewswire
    These biotechs targeting multiple neurodegenerative diseases
    A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market. 
    Via MarketBeat
    Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs
    Leading scientific and clinical experts to provide perspectives and rationale for TREM2 and progranulin targets on December 7 and December 13, respectively 
    From Alector, Inc.
    Via GlobeNewswire
    Alector to Participate in the Stifel Healthcare Conference
    From Alector, Inc.
    Via GlobeNewswire
    Alector Reports Third Quarter 2023 Financial Results and Provides Business Update
    From Alector, Inc.
    Via GlobeNewswire
    Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
    From Alector, Inc.
    Via GlobeNewswire
    Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease
    Data readout expected in Q4 2024 
    From Alector, Inc.
    Via GlobeNewswire
    Alector to Participate in Upcoming Healthcare Conferences
    From Alector, Inc.
    Via GlobeNewswire
    Alector Reports Second Quarter 2023 Financial Results and Provides Business Update
    From Alector, Inc.
    Via GlobeNewswire
    Alector to Host Mid-Year Earnings Conference Call
    Call Scheduled for Thursday, August 3, 2023, at 4:30 p.m. ET/1:30 p.m. PT 
    From Alector, Inc.
    Via GlobeNewswire
    Alector to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
    From Alector, Inc.
    Via GlobeNewswire
    Alector Reports First Quarter 2023 Financial Results and Provides Business Update
    From Alector, Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.